The current threat of the corona pandemic clearly shows how important the goal of our Cluster of Excellence RESIST is: to better understand the different susceptibility of individuals to infectious diseases in order to protect the individual.
In view of the dramatic situation, we in RESIST are currently beginning to work on protective antibodies against SARS-CoV2 and we have started to test potential coronavirus vaccines in preclinical trials.
Further research activities related to SARS-CoV2 are also starting in the RESIST institutions: Teams from the MHH, the TWINCORE Centre for Experimental and Clinical Infection Research and the Helmholtz Centre for Infection Research want to identify new active substances with broad activity against different corona viruses, which can serve as a basis for the development of a drug that is effective against different corona viruses. Furthermore, we aim to study the response of the innate and acquired immune system against the SARS-CoV2 virus and investigate whether there is a genetic predisposition for severe courses of COVID-19 disease. We hope that the results will lead to new approaches for antiviral therapies and their targeted, individual control.
Professor Schulz answered numerous questions about the novel coronavirus, together with MHH colleagues. The interview (in German) can be found here (on the homepage of the Hanover Medical School).